Mostrar el registro sencillo del ítem
Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study.
dc.contributor.author | Núñez, Julio | |
dc.contributor.author | Palau, Patricia | |
dc.contributor.author | Domínguez Mafé, Eloy | |
dc.contributor.author | Mollar, Anna | |
dc.contributor.author | Núñez, Eduardo | |
dc.contributor.author | Ramón, José María | |
dc.contributor.author | Miñana, Gema | |
dc.contributor.author | Santas, Enrique | |
dc.contributor.author | Facila Rubio, Lorenzo | |
dc.contributor.author | Górriz, José Luis | |
dc.contributor.author | Sanchis, Juan | |
dc.contributor.author | Bayes-Genis, Antoni | |
dc.date.accessioned | 2018-07-05T07:55:17Z | |
dc.date.available | 2018-07-05T07:55:17Z | |
dc.date.issued | 2018-04-17 | |
dc.identifier.citation | NUÑEZ, Julio; PALAU SAMPIO, Patricia; DOMÍNGUEZ MAFÉ, Eloy; MOLLAR, Anna; NUÑEZ, Eduardo; RAMÓN, José María; MIÑANA, Gema; SANTAS, Enrique; FÁCILA, Lorenzo; GÓRRIZ, José L.; SANCHIS, Juan; BAYÉS-GENÍS, Antoni, (2018). Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study. Clinical Cardiology, v. 41, issue 4, p. 476-480 | ca_CA |
dc.identifier.uri | http://hdl.handle.net/10234/175479 | |
dc.description.abstract | Background: Sodium-glucose linked transporter 2 inhibition recently emerged as a promising ther- apy for reducing the risk of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). However, there is a lack of data endorsing its role in symptomatic HF patients. We sought to eval- uate the short-term effects of empagliflozin on maximal exercise capacity in these patients. Hypothesis: We postulate tretament with empagliflozin may improve functional capacity in patients with T2DM and established HF. Methods: Nineteen T2DM patients with symptomatic HF were prospectively included and underwent cardiopulmonary exercise testing before and 30 days after initiation of empagliflo- zin therapy. A mixed-effects model for repeated measures was used. Results: Median patient age was 72 years (interquartile range, 60–79 years); 42.1% were in New York Heart Association class III. Baseline mean ( SD) peak oxygen consum ption (peak VO 2 ) was 10.9 4. 0 mL/ min /k g. P eak VO 2 increased significantly at 30 days (∆: +1.21 [0.66 to 1.76] mL/min/kg; P < 0.001). A significant improvement in ventilatory efficiency during exercise, 6-minute walking distance, and quality of life, and a reduction in antigen carbohydrate 125, were also found. Estimated glomerular filtration rate and natriuretic peptides did not significantly change. Conclusions: In this pilot study, empagliflozin was associated with 1-month improvement in exercise capacity in T2DM patients with symptomatic HF. This beneficial effect was also found for other surrogates of severity. | ca_CA |
dc.format.extent | 5 p. | ca_CA |
dc.language.iso | eng | ca_CA |
dc.publisher | Wiley | ca_CA |
dc.rights.uri | http://rightsstatements.org/vocab/CNE/1.0/ | * |
dc.subject | Empagliflozin | ca_CA |
dc.subject | Exercise Capacity | ca_CA |
dc.subject | Heart Failure | ca_CA |
dc.title | Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study. | ca_CA |
dc.type | info:eu-repo/semantics/article | ca_CA |
dc.identifier.doi | https://doi.org/10.1002/clc.22899 | |
dc.relation.projectID | This work was supported in part by grants from CIBER Cardiovascular (16/11/00420, 16/11/00403), FEDER, and PIE (15/00013). | |
dc.rights.accessRights | info:eu-repo/semantics/restrictedAccess | ca_CA |
dc.relation.publisherVersion | https://onlinelibrary.wiley.com/doi/abs/10.1002/clc.22899 | ca_CA |
dc.type.version | info:eu-repo/semantics/publishedVersion | ca_CA |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
MED_Articles [671]
Articles de publicacions periòdiques